Schizophrenia News

The Janssen Pharmaceutical Companies of Johnson & Johnson announced FDA approval of Invega Hafyera, a twice-yearly injectable antipsychotic for adults with schizophrenia.

Researchers identified a correlation between low doses of antipsychotics and relapse prevention in schizophrenia, according to findings published in JAMA Psychiatry.

In people with severe psychiatric disorders, psychosocial factors and positive psychology were important in predicting subjective well-being, according to a Spanish study published in Comprehensive Psychiatry.

Austedo treatment appeared to improve involuntary movements and quality of life among older adults with tardive dyskinesia, according to results of a post hoc analysis of a long-term open-label extension study.

Individuals with schizophrenia had lower COVID-19 vaccination rates than the general population despite having higher hospitalization and mortality risk, according to results of a longitudinal cohort study.

Schizophrenia genetic liability correlated with higher disorganized dimension scores but not other symptom dimensions, according to results of a genetic association study published in JAMA Psychiatry.

The Danish OPUS early intervention services for first-episode psychosis improved several patient outcomes, according to results of a phase 4 prospective cohort study that compared randomized trial with real-world data.

Ketamine did not appear to worsen psychotic symptoms among predisposed patients, according to results of a systematic review published in Journal of Clinical Psychiatry.

Preexisting mental disorders, particularly psychotic and mood disorders, as well as exposure to antipsychotics and anxiolytics, increased risk for COVID-19-related mortality.

The proportion of schizophrenia cases linked to cannabis use disorder increased three- to fourfold in the past 2 decades, according to results of a nationwide prospective cohort study published in JAMA Psychiatry.